[ad_1]
Taipei City – 
announced the closing of its initial public offering (the “Offering”) of 9,000,000
units at $10.00 per unit. Each unit consists of one share of Class A common
stock and one redeemable warrant. The underwriters exercised their
over-allotment option in full for an additional 1,350,000 units at the time of
the closing of the Offering. As a result, the aggregate gross proceeds of the
Offering, including the over-allotment, is approximately $103.5 million, prior
to deducting underwriting discounts, commissions, and other Offering expenses.
The
Company is a blank check company formed for the purpose of effecting a merger,
capital stock exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses. While the Company may
pursue an initial business combination target in any business or industry, it intends
to focus on industries that complement its management team’s background and to
capitalize on the ability of the management team to identify and acquire a
business where the management team has extensive experience. Sectors the Company
plans on exploring include, but are not limited to, the healthcare and
technology industries, specifically within the biotechnology and pharmaceutical
sectors.
The Company
is sponsored by an affiliate of Maxpro Ventures Ltd., a respected Taiwan based
venture capital firm specialized in the healthcare industry.
EF
Hutton, division of Benchmark Investments, LLC, acted as sole book running
manager for the offering.
The
offering was made only by means of a prospectus. Copies of the prospectus may
be obtained from EF Hutton, division of Benchmark Investments LLC, Attn:
Syndicate Department, 590 Madison Ave., 39th Floor, New York, New York 10022, by
telephone at (212) 404-7002, by fax at (646) 861-4697, or by email at
syndicate@efhuttongroup.com.
A
registration statement relating to these securities has been filed with, and
declared effective by, the Securities and Exchange Commission on October 7,
2021. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
FORWARD-LOOKING
STATEMENTS
This
press release contains statements that constitute “forward-looking statements,”
including with respect to the initial public offering and the anticipated use
of the net proceeds. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all, or that the net
proceeds of the offering will be used as indicated. Forward-looking statements
are subject to numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of the Company’s
registration statement and preliminary prospectus for the offering filed with
the Securities and Exchange Commission (“SEC”). Copies are available on the
SEC’s website, www.sec.gov. The Company undertakes no obligation to update
these statements for revisions or changes after the date of this release,
except as required by law.
Contact
Maxpro Capital
Acquisition Corp.
5/F-4, No. 89
Songren Road, Xinyi
District
Taipei City 11073
Attn: Moses Chen
Chief Executive Officer
m.chen@maxproventures.com
+886 2 7713
7952
[ad_2]